Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial

Journal of Clinical Oncology

Volumn 13, Issue 1, 1995, Pages 239-250

  Lew, Michael A ^a   Kehoe, Kay ^a   Ritz, Jerome ^a   Antman, Karen H ^a   Nadler, Lee ^a   Kalish, Leslie A ^a   Finberg, Robert ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEZLOCILLIN; VANCOMYCIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENTEROCOLITIS; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RATE; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0028854228     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1995.13.1.239     Document Type: Article

References (78)

1. Armstrong D: Infections in patients with neoplastic disease, in Verhoef J, Peterson PK, Quie PG (eds): Infections in the Immunocompromised Host - Pathogenesis, Prevention and Therapy. Amsterdam, the Netherlands, Elsevier/North-Holland, 1980, pp 129-158
2. Young LS: Management of infections in leukemia and lymphoma, in Rubin RH, Young LS (eds): Clinical Approach to Infection in the Compromised Host (ed 2). New York, NY, Plenum, 1981, pp 461-506
3. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with leukemia. Ann Intern Med 64:328-340, 1966
4. Meyers JD: Infection in bone marrow transplant recipients. Am J Med 81:27-38, 1986 (suppl A)
5. Meyers JD, Thomas ED: Infection complicating bone marrow transplantation, in Rubin RH, Young LS (eds): Clinical Approach to Infection in the Compromised Host (ed 2). New York, NY, Plenum, 1988, pp 525-556
6. Schimpff SC, Young VM, Greene WH, et al: Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 77:707-714, 1972
7. Levine AS, Siegel SE, Schreiber AD, et al: Protected environments: A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 288:477-483, 1973
8. Yates JW, Holland JF: A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 32:1490-98, 1973
9. Schimpff SC, Green WH, Young VM, et al: Infection prevention in acute nonlymphocytic leukemia: Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 82:351-358, 1975
10. EORTC Gnotobiotic Group: Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. Infection 6:175-191, 1978
11. Rodriguez V, Bodey GP, Freircich EJ, et al: Randomized trial of protected environment-prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore) 57:253-266, 1978
12. Storring RA, Jameson B, McElwain TJ, et al: Oral nonabsorbable antibiotics prevent infection in acute lymphoblastic leukemia. Lancet 2:837-840, 1977
13. Bender JF, Schimpff SC, Young VM, et al: A comparative trial of tobramycin vs gentamicin in combination with vancomycin and nystatin for alimentary tract suppression in leukemia patients. Eur J Cancer 15:35-44, 1979
14. van der Waajj D, Berghuis JM, Lekkerkerk JEC: Colonization resistance of the digestive tract of mice during systemic antibiotic treatment. J Hyg 70:605-610, 1972
15. Wade JC, Schimpff SC, Newman KA, et al: Staphylococcus epidermidis: An increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97:503-508, 1982
16. Winston DJ, Dudnick DV, Chapin M, et al: Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 143:32-36, 1983
17. Gurwith MJ, Brunton HL, Lank BA, et al: A prospective controlled investigation of prophylactic trimethoprim-sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 66:248-256, 1979
18. Enno A, Catovsky D, Darrell J, et al: Cotrimoxazole for prevention of infection in acute leukemia. Lancet 2:395-397, 1978
19. Starke ID, Catovsky D, Darrell J, et al: Cotrimoxazole alone for prevention of bacterial infection in patients with acute leukemia. Lancet 1:5-6, 1982
20. Dekker AW, Rozenberg-Arska M, Sixma JJ, et al: Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphoblastic leukemia. Ann Intern Med 95:555-9, 1981
21. Wade JC, Schimpff SC, Hargadon MT, et al: A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 304:1057-62, 1981
22. Watson JG, Jameson B, Powles RL, et al: Cotrimoxazole vs. nonabsorbable antibiotics in acute leukemia. Lancet 1:6-9, 1982
23. Pizzo PA, Robichaud KJ, Brenda KE, et al: Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial. J Pediatr 102:125-33, 1983
24. Wade JC, DeJongh CA, Newman KA, et al: Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: Trimethoprim-sulfamethoxazole vs. nalidixic acid. J Infect Dis 147:624-634, 1983
25. Calvo F, Marty M, Lepors JS, et al: Antibiotic prophylaxis against infections in acute leukemia. Lancet 1:583-584, 1981
26. Weiser B, Lange M, Fialk MS, et al: Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial. Ann Intern Med 95:436-438, 1981
27. Gualtieri RJ, Donowitz GR, Kaiser DL, et al: Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 74:934-940, 1983
28. Kramer BS, Carr DJ, Rand KH, et al: Prophylaxis of fever and infection in adult cancer patients. A placebo-controlled trial of oral trimethoprim-sulfamethoxazole plus erythromycin. Cancer 53:329-335, 1984
29. Riben PD, Louie TJ, Lank BA, et al: Reduction in mortality from gram-negative sepsis in neutropenic patients receiving trimethoprim/sulfamethoxazole therapy. Cancer 51:1587-1592, 1983
30. Goorin AM, Hershey BJ, Levin MJ, et al: Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediair Infect Dis 4:265-269, 1985
31. Wilson JM, Guiney DG: Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia. Isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. N Engl J Med 306:16-20, 1982
32. Henry S, Chemoprophylaxis of bacterial infections in granulocytopenic patients. Am J Med 76:654-651, 1984
33. Young LS, Antimicrobial prophylaxis against infection in neutropenic patients. J Infect Dis 147:611-614, 1983
34. Karp JE, Merz WG, Hendricksen C, et al: Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 106:1-7, 1987
35. Winston DJ, Ho WG, Nakao SL, et al: Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 80:884-890, 1986
36. Bow EJ, Rayner E, Louie TJ: Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. Am J Med 84:847-853, 1988
37. Rozenberg-Arska M, Dekker AW, Verhoef J: Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: The effect on fecal flora. J Infect Dis 152:104-107, 1985
38. Dekker AW, Rozenberg-Arska M, Verhoef J: Infection prophylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 106:7-12, 1987
39. Maschmeyer G, Haralambie E, Gaus W, et al: Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia. Infection 16:98-104, 1988
40. DePauw BE, Donnelly JP, DeWitte T, et al: Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant patients. Bone Marrow Transplant 5:179-82, 1990
41. Lew MA, Kehoe K, Ritz J, et al: Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51:630-636, 1991
42. Anonymous. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. Ann Intern Med 115:7-12, 1991
43. Winston DJ, Ho WG, Bruckner DA, et al: Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 88:36-42, 1990
44. Liang RHS, Yung RWH, Chan T, et al: Ofloxacin versus cotrimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 34:215-218, 1990
45. Hooper DC, Wolson JS. The fluoroquinolones: Pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 28:716-721, 1985
46. Antman K, Ayash L, Elias A, et al: A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measureable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10:102-110, 1992
47. Freedman AS, Takvorian T, Anderson KC, et al: Autologous bone marrow transplantation in B cell non-Hodgkin's lymphoma: Very low treatment related mortality in 100 patients in sensitive relapse. J Clin Oncol 8:784-791, 1990
48. Elias AD, Ayash L, Anderson K, et al: Recruitment of peripheral blood progenitor cells by GM-CSF and chemotherapy as hematologic support during high dose intensification for breast cancer. Blood 79:3036-3044, 1992
49. Soiffer RJ, Murray C, Mauch P, et al: Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191-1200, 1992
50. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
51. Pizzo PA, Hathorn JW, Hiemenz, et al: A randomized trial comparing ceftazidime alone with combination therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558, 1986
52. Fleming LW, Moreland TA, Stewart WK, et al: Ciprofloxacin and antacids. Lancet 2:294, 1986 (letter)
53. Barry AL, Thornsberry C: Susceptibility tests: diffusion test procedures, in Lennette EH, Balows A, Hawler WJ Jr, Shadomy HJ (eds): Manual of Clinical Microbiology. Washington, DC, American Society for Microbiology, 1985, pp 978-987
54. Baker CN, Stocker SA, Rhoden DL, et al: Evaluation of the MicroScan antimicrobial susceptibility system with the autoSCAN-4 automated reader. J Clin Microbiol 23:143-148, 1986
55. NCCLS: Performance Standards for Antimicrobial Susceptibility Testing. Third informational supplement. M100-S3. Villanova, PA, National Committee for Clinical Laboratory Standards, 1991
56. Wu TC, Gersch SM: Evaluation of a commercial kit for the routine detection of Clostridium difficile cytotoxin by tissue culture. J Clin Microbiol 23:143-148, 1986
57. Scholl H, Schmidt K, Weber B: Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. J Chromatogr 416:321-330, 1987
58. O'Brien PC, Flemming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-566, 1979
59. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 78:427-434, 1983
60. Kaplan EL, Meier R: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
61. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
62. Lehmann EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden Day, 1975
63. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc 135:185-206, 1972
64. Snedecor SW, Cochran WC: Statistical Methods (ed 8). Ames, IA, Iowa State University, 1989
65. Sanders CC, Sanders WE, Goering RV: Overview of preclinical studies with ciprofloxacin. Am J Med 82:2-11, 1987
66. Cohen J, Donnelly HP, Wordley AM et al: Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet 1:1452-1454, 1983
67. Kayser FH, Novak J: In vitro activity of ciprofloxacin against gram-positive bacteria. Am J Med 82:33-39, 1987
68. Chow AW, Cheng N, Bartlet KH. In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics. Antimicrob Agents Chemother 28:842-844, 1985
69. Delmee M, Avesani V. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 29:374-375, 1986
70. Brumfitt W, Franklin I, Grady D, et al: Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 26:757-761, 1984
71. Brogard JM, Jehl F, Monteil H, et al: Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans. Antimicrob Agents Chemother 28:311-314, 1985
72. Bergan T, Delin C, Johansen S, et al: Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother 29:298-302, 1986
73. EORTC International Antimicrobial Therapy Cooperative Group: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 137:14-29, 1978
74. Elting LS, Bodey GP, Keefe BH: Septicemia and shock syndrome due to viridans streptococci: A case-controlled study of predisposing factors. Clin Infect Dis 14:1201-1207, 1992
75. Villablanca JG, Steiner M, Kersey J, et al: The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 5:387-393, 1990
76. Classen DC, Burke JP, Ford CD, et al: Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 89:441-446, 1990
77. Weisman SJ, Scoopo FJ, Johnson GM, et al: Septicemia in pediatric oncology patients: The significance of viridans streptococcal infections. J Clin Oncol 8:453-459, 1990
78. Sotiropoulos SV, Jackson MA, Woods GM, et al: Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J 8:755-758, 1989.